Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study

Hemelrijck, Mieke Van; Walldius, Göran; Jungner, Ingmar; Hammar, Niklas; Garmo, Hans; Binda, Elisa; Hayday, Adrian; Lambe, Mats; Holmberg, Lars

doi:10.1007/s10552-011-9774-z

Cited by 61 publications

(77 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, several other pathways that are considered vital for carcinogenesis, such as the sonic hedgehog and Akt pathways, are also cholesterol-sensitive [39,40]. Apo A is the major component of HDL particles [41] and can reduce the levels of free TNF-α, which results in attenuated tumor formation [42]. Low levels of Apo A may therefore contribute to inflammatory processes linked to tumor biology.…”

Section: Discussionmentioning

confidence: 99%

“…For example, low Apo A levels were found to be associated with a higher risk of breast cancer [43], and for ovarian cancer, Apo A is one of the biomarkers that was shown to potentially improve early detection [44]. Apo A is more strongly linked to prostate cancer risk than Apo B [41], and we did not find any evidence for an association between pancreatic adenocarcinoma and other lipid components (Apo B, Tri, or LDL). However, it is possible that there are distinct etiological relationships between lipid profiles and pancreatic adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Syndrome Components and Risk Factors for Pancreatic Adenocarcinoma: A Case-Control Study in China

Chen

et al. 2012

Digestion

View full text Add to dashboard Cite

Background: Metabolic syndrome is a complex collection of interrelated conditions. Recent data have shown that metabolic syndrome may play a role in several cancers. Pancreatic adenocarcinoma is the fourth most common cause of death from cancer in the United States and the fifth in Europe. Despite the increasing numbers of published studies, the etiology of pancreatic adenocarcinoma is incompletely defined. Therefore, this paper aims to evaluate the risk factors for pancreatic adenocarcinoma. Methods: This was a case-control study of pancreatic adenocarcinoma patients who were referred to the Peking Union Medical College Hospital. Controls were randomly selected from an existing database of healthy individuals at the Health Screening Center. Data on metabolic syndrome, pancreatic diseases, liver diseases, and a history of diabetes and history of hypertension were collected either by conducting a retrospective review of the patients’ records and health examination reports or by interview. Results: A history of smoking (OR = 2.981), diabetes (OR = 2.421), cholecystolithiasis (OR = 5.453), or chronic pancreatitis (OR = 28.264) as well as the levels of fasting blood glucose (OR = 4.241), total cholesterol (OR = 1.793), and apolipoprotein A (OR = 36.065) were significantly related to pancreatic adenocarcinoma. Conclusions: Cholelithiasis, chronic pancreatitis, and certain metabolic syndrome components are potential risk factors for the development of pancreatic adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome Components and Risk Factors for Pancreatic Adenocarcinoma: A Case-Control Study in China

Chen

et al. 2012

Digestion

View full text Add to dashboard Cite

show abstract

“…Coefficients of variation (CV) for these replicate samples were 2.2 % for total cholesterol, 2.2 % for LDL cholesterol, and 1.5 % for HDL cholesterol. Non-HDL cholesterol, which has been examined in other studies of cholesterol and prostate cancer [11,28], was calculated by subtracting HDL cholesterol from total cholesterol.…”

Section: Cholesterol Measurementmentioning

confidence: 99%

Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Jacobs

Stevens

Newton

et al. 2012

Cancer Causes Control

View full text Add to dashboard Cite

“…Dyslipidaemia associated with the metabolic syndrome, including increased triglycerides and LDL and decreased HDL, is also associated with increased prostate cancer risk [11–13], and cholesterol-lowering medications such as statins are currently believed to exert most of their positive effects via systemic reductions in total cholesterol [14]. Both dietary and de novo synthesis of free fatty acids have been shown to promote prostate cancer cell survival [15, 16], but studies which characterise fatty acid profiles in prostate disease remain controversial [17, 18].…”

Section: Prostate Cancer and The Metabolic Syndromementioning

confidence: 99%

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

Gunter

Lubik

McKenzie

et al. 2012

Advances in Urology

View full text Add to dashboard Cite

An association between the metabolic syndrome and reduced testosterone levels has been identified, and a specific inverse relationship between insulin and testosterone levels suggests that an important metabolic crosstalk exists between these two hormonal axes; however, the mechanisms by which insulin and androgens may be reciprocally regulated are not well described. Androgen-dependant gene pathways regulate the growth and maintenance of both normal and malignant prostate tissue, and androgen-deprivation therapy (ADT) in patients exploits this dependence when used to treat recurrent and metastatic prostate cancer resulting in tumour regression. A major systemic side effect of ADT includes induction of key features of the metabolic syndrome and the consistent feature of hyperinsulinaemia. Recent studies have specifically identified a correlation between elevated insulin and high-grade PCa and more rapid progression to castrate resistant disease. This paper examines the relationship between insulin and androgens in the context of prostate cancer progression. Prostate cancer patients present a promising cohort for the exploration of insulin stabilising agents as adjunct treatments for hormone deprivation or enhancers of chemosensitivity for treatment of advanced prostate cancer.

show abstract

Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study

Abstract: Our results show that low HDL and ApoA-I as well as increased lipid ratios are related to increased PCa risk. Experimental studies are required to tease out the underlying biological mechanisms linking these lipid components to PCa.

Cited by 61 publications

References 36 publications

Metabolic Syndrome Components and Risk Factors for Pancreatic Adenocarcinoma: A Case-Control Study in China

Metabolic Syndrome Components and Risk Factors for Pancreatic Adenocarcinoma: A Case-Control Study in China

Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

Contact Info

Product

Resources

About